reports
- ABGSC Energy Research
- Daniel Vårdal Haugland
- Herman Caspersen
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Stian Wibstad
Franklin Financial Services Corp: 1 director
A director at Franklin Financial Services Corp bought 2,200 shares at 48.180USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Beyond Air to Participate in the 38th Annual Roth Conference in March
Beyond Air to Participate in the 38th Annual Roth Conference in March GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 38th Annual Roth Conference being held March 22nd to 24th in Laguna Niguel, CA. 38th Annual Roth ConferenceFormat:Fireside chat and one-on-one meeti...
Viking Therapeutics Inc: 1 director
A director at Viking Therapeutics Inc maiden bought 4,475 shares at 33.500USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Core Molding Technologies Reports Full Year and Fourth Quarter 2025 Re...
Core Molding Technologies Reports Full Year and Fourth Quarter 2025 Results Fourth Quarter Total Sales Up 19.5% Driven by Elevated Tooling Revenue; Full Year Business Wins of $63 Million Support Multi-Year Revenue Expansion COLUMBUS, Ohio, March 10, 2026 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States...
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Su...
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals Ltd. (“XTL”) relating to Beyond Air’s NeuroNOS subsidiary has been terminated. The companies entered into a letter of i...
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Te...
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation. Tegoprubart has previously received orphan drug designation from the FDA for the prevention of allograft rejection in pancreatic islet cell transplantation an...
- Jonathan Moreland
VKTX VIKING THERAPEUTICS
ROCK GIBRALTAR INDUSTRIES INC.
PSTG PURE STORAGE INC. CLASS A
MNKD MANNKIND CORP.
MLAB MESA LABORATORIES INC.
FSS FEDERAL SIGNAL CORPORATION
AOSL ALPHA & OMEGA SEMICONDUCTOR
EVR EVERCORE INC CLASS A
PLBC PLUMAS BANCORP
SSP THE E.W. SCRIPPS COMPANY
TCPC BLACKROCK TCP CAPITAL CORP.
EML THE EASTERN COMPANY
TSLX SIXTH STREET SPECIALTY LENDING
ADV INC.
EOSE ADVANTAGE SOLUTIONS INC (A)
BLCO EOS ENERGY ENTERPRISES INC (A)
BAUSCH + LOMB CORP
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Pla...
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030, a first-in-class TOP1i-based ADC, on track for 3Q 2026Cash, cash equivalents and marketable securities of $189.9 million as of December 31, 2025; cash runway guidance remains into late 2027 ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceu...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- Herman Caspersen
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Stian Wibstad
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global ...
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the upcoming Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET (10:40 a.m. PT). To register in advance for the fireside chat webcast, sign up . A webcast replay will ...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of R.R. Donnelley & Sons Company and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 25 February 2026 in which we reassessed the appropriateness of the ratings in...
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management team will participate in the following investor conferences in March: TD Cowen 46th Annual Health Care Conference (Boston, MA). MacroGenics’ President and CEO, Eric Risser, will participate in a hybrid presentation and fireside chat on Tuesday, March 3, at 3:10 pm ET. MacroGenics’ manag...
MacroGenics Announces Pausing of Enrollment of New Study Participants ...
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that ta...
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATI...
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the adoption of a protocol am...
Beyond Air® Comments on Landmark Independent Review Article Highlighti...
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today commented on the publication of an independent review article providing the most comprehensive overview to date of high‑d...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- Herman Caspersen
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Stian Wibstad
Transocean Ltd. Reports Fourth Quarter and Full Year 2025 Results
Transocean Ltd. Reports Fourth Quarter and Full Year 2025 Results STEINHAUSEN, Switzerland, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) today reported financial results for the fourth quarter and full year of 2025. The Company will hold a conference call and webcast at 9 a.m. EST, 3 p.m. CET, on Friday, February 20, 2026, to discuss the results, with participation details included in this release. In addition, supplemental slides have been posted to the Investors section of the Company’s website at . 2025 KEY POINTS Operating revenues were $3.965 billion, up 13% from $...
Transocean Ltd. Provides Quarterly Fleet Status Report
Transocean Ltd. Provides Quarterly Fleet Status Report STEINHAUSEN, Switzerland, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) today issued a quarterly Fleet Status Report that provides the current status of, and contract information for, the company’s fleet of offshore drilling rigs. UPDATES This quarter’s report includes the following updates: Transocean Barents – Customer exercised a one-well option in Romania at a dayrate of $480,000.Deepwater Mykonos – Awarded a three-well contract with bp in Brazil.Deepwater Mykonos – Customer exercised a 90-day option in Brazil.D...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.